A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models by Kamel Chettab, Kamel Chettab, Chantel Fitzsimmons, Alexey Novikov, Morgane Denis, Morgane Denis, Capucine Phelip, Doriane Mathé, Pierre Antoine Choffour, Sabine Beaumel, Eric Fourmaux, Patrick Norca, David Kryza, Anne Evesque, Lars Petter Jordheim, Emeline Perrial, Eva-Laure Matera, Martine Caroff, Jerome Kerzerho, Charles Dumontet, Charles Dumontet

Get full text